Visiomode: An open-source platform for building rodent touchscreen-based behavioral assays
Journal of Neuroscience Methods · 2023
DOI: 10.1016/j.jneumeth.2022.109779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroscience Methods, 2023. Verfasst von Constantinos Eleftheriou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh EH8 9XD, UK; Centre for Discovery Brain Sciences and Patrick Wild Cent…. Hauptthemen laut MEDLINE: Rodentia, Learning. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
BACKGROUND: Touchscreen-based behavioral assays provide a robust method for assessing cognitive behavior in rodents, offering great flexibility and translational potential. The development of touchscreen assays presents a significant programming and mechanical engineering challenge, where commercial solutions can be prohibitively expensive and open-source solutions are underdeveloped, with limited adaptability. NEW METHOD: Here, we present Visiomode (www.visiomode.org), an open-source platform for building rodent touchscreen-based behavioral tasks. Visiomode leverages the inherent flexibility of touchscreens to offer a simple yet adaptable software and hardware platform. The platform is built on the Raspberry Pi computer combining a web-based interface and powerful plug-in system with an operant chamber that can be adapted to generate a wide range of behavioral tasks. RESULTS: As a proof of concept, we use Visiomode to build both simple stimulus-response and more complex visual discrimination tasks, showing that mice display rapid sensorimotor learning including switching between different motor responses (i.e., nose poke versus reaching). COMPARISON WITH EXISTING METHODS: Commercial solutions are the 'go to' for rodent touchscreen behaviors, but the associated costs can be prohibitive, limiting their uptake by the wider neuroscience community. While several open-source solutions have been developed, efforts so far have focused on reducing the cost, rather than promoting ease of use and adaptability. Visiomode addresses these unmet needs providing a low-cost, extensible platform for creating touchscreen tasks. CONCLUSIONS: Developing an open-source, rapidly scalable and low-cost platform for building touchscreen-based behavioral assays should increase uptake across the science community and accelerate the investigation of cognition, decision-making and sensorimotor behaviors both in health and disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh EH8 9XD, UK; Centre for Discovery Brain Sciences and Patrick Wild Centre, Edinburgh Medical School: Biomedical Sciences, University of Edinb…
- Centre for Discovery Brain Sciences and Patrick Wild Centre, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.
- The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, Scotland, UK.
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Eleftheriou, C., Clarke, T., Poon, V., Zechner, M., & Duguid, I. (2023). Visiomode: An open-source platform for building rodent touchscreen-based behavioral assays. Journal of Neuroscience Methods. https://doi.org/10.1016/j.jneumeth.2022.109779
Vancouver
Eleftheriou C, Clarke T, Poon V, Zechner M, Duguid I. Visiomode: An open-source platform for building rodent touchscreen-based behavioral assays. Journal of Neuroscience Methods. 2023. doi:10.1016/j.jneumeth.2022.109779
BibTeX
@article{Eleftheriou2023,
author = {Eleftheriou, Constantinos and Clarke, Thomas and Poon, V and Zechner, Marie and Duguid, Ian},
title = {Visiomode: An open-source platform for building rodent touchscreen-based behavioral assays},
journal = {Journal of Neuroscience Methods},
year = {2023},
doi = {10.1016/j.jneumeth.2022.109779}
}
EUVIMED